Journey Medical (DERM) Projected to Post Earnings on Thursday

Journey Medical (NASDAQ:DERM) is expected to post its quarterly earnings results before the market opens on Thursday, March 20th. Analysts expect Journey Medical to post earnings of ($0.22) per share for the quarter.

Journey Medical Trading Up 1.1 %

Shares of DERM stock opened at $5.31 on Tuesday. The company has a debt-to-equity ratio of 1.81, a current ratio of 1.38 and a quick ratio of 1.03. The company has a market cap of $110.93 million, a price-to-earnings ratio of -5.65 and a beta of 0.97. The stock has a 50 day simple moving average of $4.72 and a 200-day simple moving average of $5.10. Journey Medical has a 1-year low of $2.85 and a 1-year high of $6.89.

Insider Buying and Selling

In related news, CEO Claude Maraoui sold 18,147 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $5.13, for a total transaction of $93,094.11. Following the completion of the sale, the chief executive officer now directly owns 2,092,874 shares in the company, valued at approximately $10,736,443.62. The trade was a 0.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders sold 105,831 shares of company stock worth $536,622. 13.16% of the stock is owned by corporate insiders.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.